Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
about
Studies ofToxoplasma gondiiandPlasmodium falciparumenoyl acyl carrier protein reductase and implications for the development of antiparasitic agentsType I and type II fatty acid biosynthesis in Eimeria tenella: enoyl reductase activity and structureCrystal structure of enoyl-acyl carrier protein reductase (FabK) fromStreptococcus pneumoniaereveals the binding mode of an inhibitorDesign and Synthesis of Aryl Ether Inhibitors of theBacillus AnthracisEnoyl-ACP ReductaseSlow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo ActivityIdentification and Development of Novel Inhibitors of Toxoplasma gondii Enoyl ReductaseDetermination of the Crystal Structure and Active Residues of FabV, the Enoyl-ACP Reductase from Xanthomonas oryzaeStructural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) InhibitorsRational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase InhibitorDrug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosisDendralenes Branch Out: Cross-Conjugated Oligoenes Allow the Rapid Generation of Molecular ComplexityDiscovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction.Enzymes of type II fatty acid synthesis and apicoplast differentiation and division in Eimeria tenella.Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matchingStructural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI)Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.Methyl 3-(1H-indol-3-yl)propano-ate'FAS't inhibition of malaria.Anti-Toxoplasma Activity of 2-(Naphthalene-2-γlthiol)-1H Indole.Inhibiting bacterial fatty acid synthesis.The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.Fungal naphtho-γ-pyrones: Potent antibiotics for drug-resistant microbial pathogens.Direct Effect of Two Naphthalene-Sulfonyl-Indole Compounds on Toxoplasma gondii TachyzoiteSubstituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemiaThe Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010).Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs.Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.Carbon-carbon double-bond reductases in nature.Recent Advances in the C-H-Functionalization of the Distal Positions in Pyridines and Quinolines.Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015).Crystallization and preliminary X-ray analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniaePurification, crystallization and preliminary X-ray diffraction analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus mutans strain UA159AG205, a novel agent directed against FabK of Streptococcus pneumoniae.Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity.Rational questing for potential novel inhibitors of FabK from Streptococcus pneumoniae by combining FMO calculation, CoMFA 3D-QSAR modeling and virtual screening.Borane-catalyzed metal-free hydrogenation of 2,7-disubstituted 1,8-naphthyridines.
P2860
Q27643926-E546EB37-538A-4B90-846A-35DA0F4BA7A5Q27647201-9F60F3D4-4B83-4461-9B37-0049CAD20BDEQ27649956-4490E0EF-584A-4E12-8A90-42385A8106D2Q27651378-D2EEDAE4-55B9-462F-A211-5FD64A9770B4Q27653711-583760D6-8BA4-4EA1-8533-2B65545CB567Q27664019-6ABAFAF1-0F04-4549-B85C-DAAEF6F0BF8AQ27675305-F21FB8B4-438E-4219-9292-BB7450C77EBCQ27679331-50351FA6-6044-4AA9-905B-146191797CA3Q27683440-F1E8F42F-5368-4538-8080-1073C0D9C30CQ28475676-CBA83E7D-6CD8-4D32-B7D8-5942E942F8BDQ29031113-F9B3A785-3A79-4A86-9E34-DBEF9A19F4D8Q30396236-74ED8DA3-247D-4D15-BDE1-FF27B586BB94Q33579443-66C5C6DC-9462-4469-8913-18993F27D251Q34078440-A122A64B-7C27-486D-B61A-7B31AEE25DD2Q35143373-D1155B6E-BF1F-4A90-901D-5FE3ADE68345Q35216999-0362BDAF-1F4F-4167-8124-04761833A9C1Q35542526-78EFBCD8-C63A-4F32-B8CE-C666D473F73BQ35865145-E401FDAB-722A-4A69-A6D5-3DCFB745A763Q35908735-69642BDE-AF9C-41D9-9154-EB67F2578252Q36464020-1FA75286-67D9-4AAC-BFBA-D1284730D83BQ36558861-9EE3C335-413B-4257-AF9F-CDE7E9A97DE7Q36785081-B90E6D8B-27F0-4CD0-89A0-1CF9698769FFQ37283682-9B58F491-4D6A-4DD8-9A54-DE163FC851A6Q37383936-58E44399-8714-435E-A7D5-5DA027776A0CQ37544698-F480CB77-D1D2-4733-B6AD-CF9C03239AB3Q37886187-5DB46DCC-8155-4A92-BAA7-2EA3114C7478Q37979307-1644694C-37B6-463E-A93B-DD99C6F4DD66Q38019608-DE063A8C-2841-435B-B0DB-064078F35CAEQ38124842-F7A6FE83-2112-4F32-BF32-91ADBFE6223EQ38205904-DF70E67A-F0A2-44C3-B243-D433A5D2B60AQ38660527-4B75F333-6132-4516-A39C-D45BE20238CBQ38765020-B9F4AED9-A20C-4829-A23A-80B99D2B0F31Q38892242-DF08D391-AE0D-4267-82C0-2C40C515F0F8Q41870694-9F184345-955C-4803-9897-4C3DEC27C16FQ42000094-650539D5-DBB7-4B18-BF68-96B284ABD3DCQ42112414-3ED0DA2A-F238-45B7-B56E-A47F256B0432Q42237853-31E80EAC-F3AC-4C24-81EE-E49ADD915165Q47811083-A74B192E-CBE0-4504-9C0A-36D6F335CDF2Q51658617-EC40DD20-CEB4-44CC-9A77-DC21488625D0Q53075796-46ED8212-113F-49C2-8891-AEFF60AB85A9
P2860
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@ast
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@en
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@nl
type
label
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@ast
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@en
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@nl
prefLabel
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@ast
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@en
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@nl
P2093
P3181
P356
P1476
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
@en
P2093
Brian J Polizzi
Cheryl A Janson
Dalia R Jakas
David J Payne
Irene N Uzinskas
Kenneth A Newlander
Mark A Seefeld
Martha S Head
Nicola G Wallis
Patricia A Elkins
P304
P3181
P356
10.1021/JM0204035
P407
P577
2003-04-24T00:00:00Z